211 related articles for article (PubMed ID: 29941506)
21. Extended prophylaxis of venous thromboembolism with betrixaban in acutely ill medical patients with and without cancer: insights from the APEX trial.
Ageno W; Lopes RD; Yee MK; Hernandez A; Hull R; Goldhaber SZ; Gibson CM; Cohen AT
J Thromb Thrombolysis; 2020 Feb; 49(2):214-219. PubMed ID: 31493287
[TBL] [Abstract][Full Text] [Related]
22. Extended Venous Thromboembolism Prophylaxis in Medically Ill Patients: An NATF Anticoagulation Action Initiative.
Barkoudah E; Piazza G; Hecht TEH; Grant P; Deitelzweig S; Fang MC; Fanikos J; Kao CK; Barnes GD; Chen T; Ramishvili T; Schnipper JL; Goldstein JN; Ruff CT; Kaatz S; Schwartz A; Connors JM; Goldhaber SZ
Am J Med; 2020 May; 133 Suppl 1():1-27. PubMed ID: 32362349
[TBL] [Abstract][Full Text] [Related]
23. Betrixaban in the prevention of venous thromboembolism in medically ill patients.
Sylvester KW; Connors JM
Future Cardiol; 2018 Nov; 14(6):455-470. PubMed ID: 30353749
[TBL] [Abstract][Full Text] [Related]
24. Symptomatic event reduction with extended-duration betrixaban in acute medically ill hospitalized patients.
Gibson CM; Nafee T; Yee MK; Chi G; Korjian S; Daaboul Y; AlKhalfan F; Kerneis M; Goldhaber SZ; Hull R; Hernandez AF; Cohen AT; Harrington RA
Am Heart J; 2018 Apr; 198():84-90. PubMed ID: 29653652
[TBL] [Abstract][Full Text] [Related]
25. Betrixaban: Safely Reducing Venous Thromboembolic Events with Extended Prophylaxis.
Dobesh PP; Trevarrow BJ
Am J Med; 2019 Mar; 132(3):307-311. PubMed ID: 30201249
[TBL] [Abstract][Full Text] [Related]
26. Cost-Effectiveness of Betrixaban Compared with Enoxaparin for Venous Thromboembolism Prophylaxis in Nonsurgical Patients with Acute Medical Illness in the United States.
Guy H; Laskier V; Fisher M; Neuman WR; Bucior I; Deitelzweig S; Cohen AT
Pharmacoeconomics; 2019 May; 37(5):701-714. PubMed ID: 30578462
[TBL] [Abstract][Full Text] [Related]
27. Betrixaban for prevention of venous thromboembolism in acute medically ill patients.
Beyer-Westendorf J; Verhamme P; Bauersachs R
Eur Heart J Suppl; 2018 May; 20(Suppl E):E16-E22. PubMed ID: 29977165
[TBL] [Abstract][Full Text] [Related]
28. Has time come for the use of direct oral anticoagulants in the extended prophylaxis of venous thromboembolism in acutely ill medical patients? Yes.
Ageno W
Intern Emerg Med; 2018 Oct; 13(7):1009-1013. PubMed ID: 28808888
[TBL] [Abstract][Full Text] [Related]
29. Betrixaban for VTE Prevention in the Medically Ill Population, the APEX Trial: Good News for This Needy Population?
Ramacciotti E; Hoppensteadt D; Fareed J
Clin Appl Thromb Hemost; 2017 Oct; 23(7):701-702. PubMed ID: 28294628
[No Abstract] [Full Text] [Related]
30. Budget impact analysis of betrixaban for venous thromboembolism prophylaxis in nonsurgical patients with acute medical illness in the United Kingdom.
Guy H; Laskier V; Fisher M; Bucior I; Deitelzweig S; Cohen AT
Expert Rev Pharmacoecon Outcomes Res; 2020 Jun; 20(3):259-267. PubMed ID: 31215264
[TBL] [Abstract][Full Text] [Related]
31. Direct oral anticoagulants for extended-duration thromboprophylaxis in hospitalized medically ill patients: are we there yet?
Al Yami MS; Alfayez OM; Kurdi SM; Alsheikh R
J Thromb Thrombolysis; 2017 Jul; 44(1):1-8. PubMed ID: 28197755
[TBL] [Abstract][Full Text] [Related]
32. Betrixaban - the next direct factor Xa inhibitor?
Thoenes M; Minguet J; Bramlage K; Bramlage P; Ferrero C
Expert Rev Hematol; 2016 Dec; 9(12):1111-1117. PubMed ID: 27809616
[TBL] [Abstract][Full Text] [Related]
33. Prevention of Venous Thromboembolism in Acutely Ill Medical Patients: A New Era.
MacDougall K; Spyropoulos AC
Semin Respir Crit Care Med; 2021 Apr; 42(2):308-315. PubMed ID: 33548931
[TBL] [Abstract][Full Text] [Related]
34. Association of Anemia with Venous Thromboembolism in Acutely Ill Hospitalized Patients: An APEX Trial Substudy.
Chi G; Gibson CM; Hernandez AF; Hull RD; Kazmi SHA; Younes A; Walia SS; Pitliya A; Singh A; Kahe F; Kalayci A; Nafee T; Kerneis M; AlKhalfan F; Cohen AT; Harrington RA; Goldhaber SZ
Am J Med; 2018 Aug; 131(8):972.e1-972.e7. PubMed ID: 29660351
[TBL] [Abstract][Full Text] [Related]
35. Extended Thromboprophylaxis With Betrixaban or Rivaroxaban for Acutely Ill Hospitalized Medical Patients: Meta-Analysis of Prespecified Subgroups.
Jamil A; Jamil U; Singh K; Khan F; Chi G
Crit Pathw Cardiol; 2021 Mar; 20(1):16-24. PubMed ID: 32657973
[TBL] [Abstract][Full Text] [Related]
36. Anticoagulation in Venous Thromboembolism Prophylaxis in Medically Ill Patients: Potential Impact of NOACs.
Knotts TL; Mousa SA
Am J Cardiovasc Drugs; 2019 Aug; 19(4):365-376. PubMed ID: 30809772
[TBL] [Abstract][Full Text] [Related]
37. Competing risk analysis in a large cardiovascular clinical trial: An APEX substudy.
Arbetter DF; Jain P; Yee MK; Michalak N; Hernandez AF; Hull RD; Goldhaber SZ; Harrington RA; Gold A; Cohen AT; Gibson CM
Pharm Stat; 2017 Nov; 16(6):445-450. PubMed ID: 28840662
[TBL] [Abstract][Full Text] [Related]
38. Extended duration venous thromboembolism prophylaxis with betrixaban for patients re-admitted with venous thromboembolism.
Fahmy M; Sylvester KW; Migliore M; Eguale T; Fanikos J; Connors JM; Goldhaber SZ
J Thromb Thrombolysis; 2021 Jul; 52(1):22-29. PubMed ID: 33835335
[TBL] [Abstract][Full Text] [Related]
39. Betrixaban: A Novel Oral Anticoagulant With a New Niche.
Murphy G; Grace Y; Chaudry S; Chamoun R
J Pharm Technol; 2018 Jun; 34(3):123-133. PubMed ID: 34861030
[No Abstract] [Full Text] [Related]
40. The use of betrixaban for extended prophylaxis of venous thromboembolism events in hospitalized, high-risk patients.
Dobesh PP; Ahuja T; Davis GA; Fatodu H; Francis WH; Hull FP; Johnson GL; Lenchus JD; Lenoir JG; McPherson C; Nemeth J; Riello RJ
Am J Manag Care; 2018 Nov; 24(22 Suppl):S475-S482. PubMed ID: 30452199
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
